Block Listing Six Monthly Return

Scancell Holdings Plc

16 April 2024

 

Scancell Holdings plc

("Scancell" or the "Company")

Block Listing Six Monthly Return

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:

Name of applicant:			Scancell Holdings plc
Number and class of securities originally admitted:			2,880,000 ordinary shares of £0.001 each
Date of admission:			17 April 2023
Period of return:		From:	17 October 2023	To:	16 April 2024
Balance of unallotted securities under scheme(s) from previous return:			1,620,000
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):			0
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):			1,000,000
Equals: Balance under scheme(s) not yet issued/allotted at end of period:			620,000
Total number of securities in issue at the end of the period			928,979,977

For further information, please contact:
Scancell Holdings plc	[phone]
Professor Lindy Durrant, CEO Dr Jean-Michel Cosséry, Non-Executive Chairman
Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)	[phone]
Nicholas Moore/Samira Essebiyea (Healthcare Investment Banking) Nick Adams/Nick Harland (Corporate Broking)
WG Partners LLP (Joint Broker) David Wilson/Claes Spang/Sathesh Nadarajah/Erland Sternby	[phone]
Panmure Gordon (UK) Limited (Joint Broker)	[phone]
Freddy Crossley/Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)

ICR Consilium	[phone]
Mary-Jane Elliott/Angela Gray/Lindsey Neville	[e-mail]

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope^® and ImmunoBody^® for vaccines and GlyMab^® and AvidiMab^® for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope^® and ImmunoBody^®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab^®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab^®).

For further information about Scancell, please visit: https://www.scancell.co.uk/

 

END